Centogene's centocloud® set to revolutionize rare disease diagnostics with decentralized saas platform for laboratories around the world

Cambridge, mass. and rostock, germany and berlin, jan. 04, 2022 (globe newswire) -- centogene n.v. (nasdaq: cntg), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the global release of centocloud, a saas platform enabling decentralized analysis, interpretation, and reporting of genomic variants linked to rare diseases.
CNTG Ratings Summary
CNTG Quant Ranking